KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Long-Term Investments (2017 - 2023)

Pacira BioSciences has reported Long-Term Investments over the past 10 years, most recently at $2.4 million for Q4 2023.

  • Quarterly results put Long-Term Investments at $2.4 million for Q4 2023, down 93.52% from a year ago — trailing twelve months through Dec 2023 was $2.4 million (down 93.52% YoY), and the annual figure for FY2023 was $2.4 million, down 93.52%.
  • Long-Term Investments for Q4 2023 was $2.4 million at Pacira BioSciences, down from $8.3 million in the prior quarter.
  • Over the last five years, Long-Term Investments for PCRX hit a ceiling of $95.5 million in Q4 2020 and a floor of $2.4 million in Q4 2023.
  • Median Long-Term Investments over the past 5 years was $30.2 million (2019), compared with a mean of $32.5 million.
  • Biggest five-year swings in Long-Term Investments: soared 1484.13% in 2019 and later tumbled 93.52% in 2023.
  • Pacira BioSciences' Long-Term Investments stood at $11.0 million in 2019, then skyrocketed by 770.1% to $95.5 million in 2020, then tumbled by 63.37% to $35.0 million in 2021, then rose by 6.4% to $37.2 million in 2022, then tumbled by 93.52% to $2.4 million in 2023.
  • The last three reported values for Long-Term Investments were $2.4 million (Q4 2023), $8.3 million (Q1 2023), and $37.2 million (Q4 2022) per Business Quant data.